Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Andrade, Paulina ^a,b   Gimblet Ochieng, Ciara ^c   Modirian, Faraz ^a   Collins, Matthew ^c,g   Cárdenas, Maritza ^a   Katzelnick, Leah C ^a   Montoya, Magelda ^a   Michlmayr, Daniela ^a   Kuan, Guillermina ^d,e   Balmaseda, Angel ^e,f   Coloma, Josefina ^a   de Silva, Aravinda M ^c   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSIDAD SAN FRANCISCO DE QUITO   (Ecuador)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Sócrates Flores Vivas Health Center   (Nicaragua)

^e Sustainable Sciences Institute   (Nicaragua)

^f Ministry of Health   (Nicaragua)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS RNA;

ANTIBODY; CELL COMPONENT; CHEMICAL BINDING; DENGUE FEVER; IMMUNITY; INFECTIOUS DISEASE; MEMORY; SERUM; VIRUS;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; CROSS REACTION; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MEMORY CELL; SCHOOL CHILD; SEROTYPE; VIRUS NEUTRALIZATION; ZIKA FEVER; ADOLESCENT; B LYMPHOCYTE; BLOOD; CLASSIFICATION; COMPLICATION; DENGUE VIRUS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; ZIKA VIRUS;

DENGUE VIRUS; ZIKA VIRUS;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CHILD; CROSS REACTIONS; DENGUE; DENGUE VIRUS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85062153691     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-08845-3     Document Type: Article

References (68)

1. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504–507 (2013).
2. World Health Organization. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. 1–8 (1997).
3. World Health Organization. Zika Epidemiological Update. https://www.who.int/emergencies/zika-virus/classification-tables/en/ (2018).
4. Faria, N. R. et al. Zika virus in the Americas: early epidemiological and genetic findings. Science 352, 345–349 (2016).
5. Waggoner, J. J. et al. Viremia and clinical presentation in Nicaraguan patients infected with zika virus, chikungunya virus, and dengue virus. Clin. Infect. Dis. 63, 1584–1590 (2016).
6. Cao-Lormeau, V.-M. et al. Guillain–Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet 387, 1531–1539 (2016).
7. Krauer, F. et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain–Barré Syndrome: systematic review. PLoS Med. 14, e1002203–e1002227 (2017).
8. Rasmussen, S. A., Jamieson, D. J., Honein, M. A. & Petersen, L. R. Zika virus and birth defects—reviewing the evidence for causality. N. Engl. J. Med. 374, 1981–1987 (2016).
9. Pierson, T. C. & Diamond, M. S. in Fields Virology (ed. Knipe, D.) 1, 747–794 (Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2013).
10. VanBlargan, L. A., Goo, L. & Pierson, T. C. Deconstructing the antiviral neutralizing-antibody response: implications for vaccine development and immunity. Microbiol. Mol. Biol. Rev. 80, 989–1010 (2016).
11. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat. Immunol. 17, 1102–1108 (2016).
12. Smith, S. A. et al. Human monoclonal antibodies derived from memory b cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207, 1898–1908 (2013).
13. Smith, S. A. et al. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol. 88, 12233–12241 (2014).
14. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. Science 272, 54–60 (1996).
15. Purtha, W. E., Tedder, T. F., Johnson, S., Bhattacharya, D. & Diamond, M. S. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J. Exp. Med. 208, 2599–2606 (2011).
16. Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc. Natl Acad. Sci. USA 113, 728–733 (2016).
17. Wrammert, J. et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J. Virol. 86, 2911–2918 (2012).
18. Theiler, M. & Smith, H. H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787–800 (1937).
19. Hombach, J., Solomon, T., Kurane, I., Jacobson, J. & Wood, D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23, 5205–5211 (2005).
20. Niedrig, M., Lademann, M. & Emmerich, P. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop. Med. Int. Health 4, 867–871 (1999).
21. Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932 (2017).
22. Halstead, S. B. & O’Rourke, E. J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265, 739–741 (1977).
23. Patel, B. et al. Dissecting the human serum antibody response to secondary dengue virus infections. PLoS Negl. Trop. Dis. 11, e0005554 (2017). 1–15.
24. Swanstrom, J. A. et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. mBio 7, e01123 (2016). 16–8.
25. Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826 (2016).
26. Priyamvada, L. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl Acad. Sci. USA 113, 7852–7857 (2016).
27. Bardina, S. V. et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356, 175–180 (2017).
28. Terzian, A. C. B. et al. Viral load and cytokine response profile does not support antibody-dependent enhancement in dengue-primed Zika virus–infected patients. Clin. Infect. Dis. 65, 1260–1265 (2017).
29. Halai, U.-A. et al. Maternal Zika virus disease severity, virus load, prior dengue antibodies, and their relationship to birth outcomes. Clin. Infect. Dis. 65, 877–883 (2017).
30. McCracken, M. K. et al. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog. 13, e1006487–22 (2017).
31. Pantoja, P. et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat. Commun. 8, 1–13 (2017).
32. Robbiani, D. F. et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169, 597–605.e11 (2017).
33. Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).
34. Rogers, T. F. et al. Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Sci. Immunol. 2, 1–13 (2017).
35. Wang, Q. et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci. Transl. Med. 8, 369ra179–369ra179 (2016).
36. Collins, M. H. et al. Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection. Emerg. Infect. Dis. 23, 773–781 (2017).
37. Montoya, M. et al. Longitudinal analysis of antibody cross-neutralization following Zika virus and dengue virus infection in Asia and the Americas. J. Infect. Dis. 496, 504–510 (2018).
38. Andrade, P., Coloma, J. & Harris, E. ELISPOT-based ‘Multi-Color FluoroSpot’ to study type-specific and cross-reactive responses in memory B cells after dengue and Zika virus infections. Methods Mol. Biol. 1808, 151–163 (2018).
39. Mathew, A. et al. B-cell responses during primary and secondary dengue virus infections in humans. J. Infect. Dis. 204, 1514–1522 (2011).
40. Priyamvada, L. et al. B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J. Virol. 90, 5574–5585 (2016).
41. Zompi, S., Montoya, M., Pohl, M. O., Balmaseda, A. & Harris, E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS. Negl. Trop. Dis. 6, e1568–14 (2012).
42. Beltramello, M. et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271–283 (2010).
43. Amanna, I. J., Nichole, C. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007).
44. Garcia-Bates, T. M. et al. Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J. Immunol. 190, 80–87 (2012).
45. Simon-Lorière, E. et al. Increased adaptive immune responses and proper feedback regulation protect against clinical dengue. Sci. Transl. Med. 9, eaal5088–eaal5089 (2017).
46. Baumgarth, N. How specific is too specific? B-cell responses to viral infections reveal the importance of breadth over depth. Immunol. Rev. 255, 82–94 (2013).
47. Balmaseda, A. et al. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop. Med. Int. Health 11, 935–942 (2006).
48. Kostyuchenko, V. A. et al. Structure of the thermally stable Zika virus. Nature 533, 425–428 (2016).
49. Kawiecki, A. B. & Christofferson, R. C. Zika virus-induced antibody response enhances dengue virus serotype 2 replication in vitro. J. Infect. Dis. 214, 1357–1360 (2016).
50. de Alwis, R. et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl Acad. Sci. USA 1–10. 10.1073/pnas.1200566109/-/DCSupplemental/pnas.201200566SI.pdf (2012).
51. Katzelnick, L. C. et al. Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. Proc. Natl Acad. Sci. USA 115, 10762–10767 (2018).
52. Hassert, M. et al. CD4+T cells mediate protection against Zika associated severe disease in a mouse model of infection. PLoS Pathog. 14, e1007237–24 (2018).
53. Lucas, C. G. O. et al. Critical role of CD4+ T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection. Nat. Commun. 1–12. 10.1038/s41467-018-05519-4 (2018).
54. Elong Ngono, A. et al. Mapping and role of the CD8+ T cell response during primary Zika virus infection in mice. Cell Host Microbe 21, 35–46 (2017).
55. Regla-Nava, J. A. et al. Cross-reactive dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy. Nat. Commun. 1–14. 10.1038/s41467-018-05458-0 (2018)
56. Grifoni, A. et al. Prior dengue virus exposure shapes T cell immunity to Zika virus in humans. J. Virol. 91, 601–619 (2017).
57. Kuan, G. et al. The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am. J. Epidemiol. 170, 120–129 (2009).
58. Burger-Calderon, R. et al. Zika virus infection in Nicaraguan households. PLoS Negl. Trop. Dis. 12, e0006518–e0006519 (2018).
59. Waggoner, J. J. et al. Single-reaction multiplex reverse transcription PCR for detection of Zika, chikungunya, and dengue viruses. Emerg. Infect. Dis. 22, 1295–1297 (2016).
60. CDC. Trioplex Real-time RT-PCR Assay. www.fda.gov 1–66 (2017).
61. Gubler, D. J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11, 480–496 (1998).
62. Klungthong, C. et al. Dengue virus detection using whole blood for reverse transcriptase PCR and virus isolation. J. Clin. Microbiol. 45, 2480–2485 (2007).
63. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. 1–160 (2009). 9789241547871
64. Wichmann, O. et al. Dengue in Thailand and Cambodia: an assessment of the degree of underrecognized disease burden based on reported cases. PLoS Negl. Trop. Dis. 5, e996–e999 (2011).
65. Mattia, K. et al. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One 6, e27252–e27259 (2011).
66. Montoya, M. et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl. Trop. Dis. 7, e2357–10 (2013).
67. Michlmayr, D., Andrade, P., Gonzalez, K., Balmaseda, A. & Harris, E. CD14+ CD16+ monocytes are the main target of Zika virus infection in peripheral blood mononuclear cells in a paediatric study in Nicaragua. Nat. Microbiol. 1–12. https://doi.org/10.1038/s41564-017-0035-0 (2017).
68. Hadjilaou, A., Green, A. M., Coloma, J. & Harris, E. Single-cell analysis of B cell/antibody cross-reactivity using a novel multicolor fluorospot assay. J. Immunol. 195, 3490–3496 (2015).